- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03280342
Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine
Study Overview
Status
Intervention / Treatment
Detailed Description
The primary objective is to compare the effect of treatment with an immediate-release topiramate (IR-TPM), namely Topamax®, to an extended-release topiramate (XR-TPM), namely Trokendi XR®, regimen on cognition in adults with migraine.
The secondary objective is to determine the factors that explain inter-individual variability in cognitive response. Pharmacokinetic and demographic factors will be explored. Variability in cognitive response between individuals can be large. A population approach (nonlinear, mixed effects) will be used to determine drug exposure response relationships.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University Of Minnesota
-
Saint Paul, Minnesota, United States, 55114
- Prism Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Established history of episodic migraine with or without aura, as assessed by International Headache Society criteria, for at least 6 months before screening and frequency of 3 or more headache attacks per month during the past 3 months
- Male or female, ages 18-65
- Women are required to be postmenopausal, surgically incapable of bearing children, or practicing a medically acceptable method of birth control (i.e., double barrier method, IUD, Mirena, etc) for at least 1 month before study entry through 30 days following last dose.
- If postmenopausal and on hormone replacement therapy (HRT) then must to be on a stable regimen for at least 2 months (continuous stable regimen of cyclic or non-cyclic HRT); negative pregnancy test.
- Native English speakers (due to speech and language analysis)
- Montreal Cognitive Assessment (MoCA) score equal to or greater than 26.
Exclusion Criteria:
- Onset of migraine occurred after age 50 years, or overuse of analgesics or migraine specific agents for the acute treatment of migraine episodes; examples of analgesic overuse included the following: more than 8 treatment episodes (episode defined as any calendar day of usage) of ergot containing medications a month; more than 8 treatment episodes of triptans a month; or more than 6 treatment episodes of potent opioids a month.
- Required, continued use of the following medications for any medical reason during the study: beta-blockers, benzodiazepines, tricyclic antidepressants, antiepileptics, calcium channel blockers, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) daily, opioids, agents for insomnia (e.g., Ambien, diphenhydramine-containing OTC products); corticosteroids, local anesthetics, botulinum toxin within last three months, or herbal preparations such as feverfew or St John's wort. However, subjects will be permitted to be on a stable regimen of a selective serotonin reuptake inhibitor or SNRI for 3 months or more for depression and/or anxiety.
- A history of nephrolithiasis
- Have previously taken topiramate
- Received an experimental drug or used an experimental or approved device for migraine prevention (e.g., TENIS unit) within 30 days of screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: IR-TPM (Topamax)
|
XR-TPM (Trokendi XR)
XR-TPM (Trokendi XR)
|
Active Comparator: XR-TPM (Trokendi XR)
|
XR-TPM (Trokendi XR)
XR-TPM (Trokendi XR)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Controlled Oral Word Association Test (COWA)-generative phonemic fluency
Time Frame: Baseline (Day 1) through Day 52
|
The primary outcome measure is the Controlled Oral Word Association (COWA: phonemic generative fluency).
COWA was chosen as the primary endpoint since in previous studies of drug-induced cognitive impairment, this measure was sensitive to the effects of topiramate (Meador et al, 2003; Marino et al, 2012; Marino et al, 2015).
The primary endpoint is a change in the COWA score from baseline to each post-dose assessment
|
Baseline (Day 1) through Day 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measures of semantic verbal fluency
Time Frame: Baseline (Day 1) through Day 52
|
Change in scores from individual baseline to each post-dose assessment on measures of semantic verbal fluency (e.g., Animals)
|
Baseline (Day 1) through Day 52
|
Digit Span Backward
Time Frame: Baseline (Day 1) through Day 52
|
Change in scores from individual baseline to each post-dose assessment on measures of working memory (i.e., Digit Span Backward)
|
Baseline (Day 1) through Day 52
|
Digit Symbol Modalities Test (SDMT)
Time Frame: Baseline (Day 1) through Day 52
|
Change in scores from individual baseline to each post-dose assessment on measure of psychomotor speed
|
Baseline (Day 1) through Day 52
|
Trails A & B
Time Frame: Baseline (Day 1) through Day 52
|
Change in scores from individual baseline to each post-dose assessment on measures of executive function
|
Baseline (Day 1) through Day 52
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Susan Marino, PhD, University Of Minnesota
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FWA00000312-10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on IR-TPM (Topamax)
-
Supernus Pharmaceuticals, Inc.Completed
-
Université de SherbrookeRecruitingEpilepsy; Seizure | Chronic Subdural Hematoma | Cortical Depression; Cortical Depolarization | Nonepileptic, Stereotypical and Intermittent Symptoms | NESISCanada
-
Supernus Pharmaceuticals, Inc.Completed
-
Bial - Portela C S.A.Completed
-
Bioxodes S.A.Completed
-
Federal University of São PauloUnknownQuality of Life | Cellulitis
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedMelanoma | Small Cell Lung Cancer | Colorectal Neoplasms | Ovarian Neoplasms | LiposarcomaUnited States
-
Bioxodes S.A.Recruiting
-
Stallergenes GreerCompletedRhinitis, Allergic, Perennial | House Dust Mite AllergyFrance, United States
-
F2G Biotech GmbHQuotient ClinicalCompleted